Data from electronic health records aren’t always helpful for oncologists, which is why the founders of Cancer Outcomes Tracking and Analysis (COTA) developed a platform that stratifies patients by relevant characteristics, said Stuart Goldberg, MD, chief medical officer, COTA, John Theurer Cancer Center.
Data from electronic health records aren’t always helpful for oncologists, which is why the founders of Cancer Outcomes Tracking and Analysis (COTA) developed a platform that stratifies patients by relevant characteristics, said Stuart Goldberg, MD, chief medical officer, COTA, John Theurer Cancer Center.
Transcript (slightly modified)
What makes the COTA platform different from traditional data analysis programs?
Today most people use electronic health records, and they were really set up for billing purposes. They’re all based on IC-9 or IC-10, which are very broad characteristics that are helpful to the billing coders, but not insightful to the oncologist. So we’ve developed an entire system that’s based on stratifying the patients by the patient characteristics. It could be the size of the tumor, it could be genomics, it could be patient factors, like heart disease or diabetes.
We put all that into a digital code so that then we can do analytics. That’s very different than just boiling the ocean, looking for some type of insight to come out. As oncologists, when we founded COTA, we understood what we needed to look for, and we organized the patients around oncology-specific factors that every oncologist would understand readily.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More